{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:44:09Z","timestamp":1790009049606,"version":"4.0.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSC 104-2320-B-006-008-MY3"],"award-info":[{"award-number":["NSC 104-2320-B-006-008-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12933-016-0350-4","type":"journal-article","created":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T07:24:32Z","timestamp":1456817072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study"],"prefix":"10.1186","volume":"15","author":[{"given":"Huang-Tz","family":"Ou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Shang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,1]]},"reference":[{"issue":"7","key":"350_CR1","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.2337\/diacare.21.7.1138","volume":"21","author":"K Gu","year":"1998","unstructured":"Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971\u20131993. Diabetes Care. 1998;21(7):1138\u201345.","journal-title":"Diabetes Care"},{"key":"350_CR2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1475-2840-9-54","volume":"9","author":"CH Jorgensen","year":"2010","unstructured":"Jorgensen CH, Gislason GH, Andersson C, Ahlehoff O, Charlot M, Schramm TK, Vaag A, Abildstrom SZ, Torp-Pedersen C, Hansen PR. Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention\u2013a retrospective nationwide cohort study. Cardiovasc Diabetol. 2010;9:54.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"350_CR3","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/pds.1630","volume":"17","author":"DJ Margolis","year":"2008","unstructured":"Margolis DJ, Hoffstad O, Strom BL. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf. 2008;17(8):753\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"24","key":"350_CR4","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457\u201371.","journal-title":"N Engl J Med"},{"key":"350_CR5","doi-asserted-by":"crossref","first-page":"d1309","DOI":"10.1136\/bmj.d1309","volume":"342","author":"YK Loke","year":"2011","unstructured":"Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ. 2011;342:d1309.","journal-title":"BMJ"},{"issue":"9681","key":"350_CR6","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","volume":"373","author":"PD Home","year":"2009","unstructured":"Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ, Team RS. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125\u201335.","journal-title":"Lancet"},{"issue":"9131","key":"350_CR7","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854\u201365.","journal-title":"Lancet"},{"issue":"4","key":"350_CR8","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","volume":"290","author":"J-L Chiasson","year":"2003","unstructured":"Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Group S-NTR: acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290(4):486\u201394.","journal-title":"JAMA"},{"issue":"9323","key":"350_CR9","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","volume":"359","author":"J-L Chiasson","year":"2002","unstructured":"Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Group S-NTR: acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359(9323):2072\u20137.","journal-title":"Lancet"},{"issue":"22","key":"350_CR10","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"9840","key":"350_CR11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(12)60691-6","volume":"380","author":"B Gallwitz","year":"2012","unstructured":"Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, Dugi KA, Woerle H-J. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475\u201383.","journal-title":"Lancet"},{"issue":"14","key":"350_CR12","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317\u201326.","journal-title":"N Engl J Med"},{"issue":"14","key":"350_CR13","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327\u201335.","journal-title":"N Engl J Med"},{"issue":"3","key":"350_CR14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232\u201342.","journal-title":"N Engl J Med"},{"issue":"10","key":"350_CR15","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/dom.12314","volume":"16","author":"U Mogensen","year":"2014","unstructured":"Mogensen U, Andersson C, Fosb\u00f8l E, Schramm T, Vaag A, Scheller NM, Torp-Pedersen C, Gislason G, K\u00f8ber L. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus\u2013a retrospective nationwide study. Diabetes Obes Metab. 2014;16(10):1001\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"350_CR16","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00592-014-0663-2","volume":"51","author":"SC Kim","year":"2014","unstructured":"Kim SC, Glynn RJ, Liu J, Everett BM, Goldfine AB. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. Acta Diabetol. 2014;51(6):1015\u201323.","journal-title":"Acta Diabetol"},{"issue":"10","key":"350_CR17","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/dom.12306","volume":"16","author":"CL Morgan","year":"2014","unstructured":"Morgan CL, Mukherjee J, Jenkins-Jones S, Holden S, Currie C. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. Diabetes Obes Metab. 2014;16(10):977\u201383.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"350_CR18","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/dme.12800","volume":"32","author":"YC Chang","year":"2015","unstructured":"Chang YC, Chuang LM, Lin JW, Chen ST, Lai MS, Chang CH. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study. Diabet Med. 2015;32(11):1460\u20139.","journal-title":"Diabet Med"},{"key":"350_CR19","doi-asserted-by":"crossref","unstructured":"Ou S-M, Shih C-J, Chao P-W, Chu H, Kuo S-C, Lee Y-J, Wang S-J, Yang C-Y, Lin C-C, Chen T-J. Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus. Ann Intern Med. 2015.","DOI":"10.7326\/M15-0308"},{"issue":"36","key":"350_CR20","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1093\/eurheartj\/ehv301","volume":"36","author":"GP Fadini","year":"2015","unstructured":"Fadini GP, Avogaro A, Degli Esposti L, Russo P, Saragoni S, Buda S, Rosano G, Pecorelli S, Pani L. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. Eur Heart J. 2015;36(36):2454\u201362.","journal-title":"Eur Heart J"},{"key":"350_CR21","doi-asserted-by":"crossref","unstructured":"Kannan S, Pantalone KM, Matsuda S, Wells BJ, Karafa M, Zimmerman RS. The risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: a large database study from Cleveland Clinic. J Diabetes. 2015.","DOI":"10.1111\/1753-0407.12301"},{"issue":"11","key":"350_CR22","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245\u201351.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"350_CR23","first-page":"15","volume":"14","author":"BA Young","year":"2008","unstructured":"Young BA, Lin E, Von Korff M, Simon G, Ciechanowski P, Ludman EJ, Everson-Stewart S, Kinder L, Oliver M, Boyko EJ, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care. 2008;14(1):15\u201323.","journal-title":"Am J Manag Care"},{"issue":"11","key":"350_CR24","first-page":"721","volume":"18","author":"H-Y Chang","year":"2012","unstructured":"Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721\u20136.","journal-title":"Am J Manag Care"},{"issue":"5","key":"350_CR25","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jdiacomp.2014.05.011","volume":"28","author":"H-L Chen","year":"2014","unstructured":"Chen H-L, Hsiao F-Y. Risk of hospitalization and healthcare cost associated with Diabetes Complication Severity Index in Taiwan\u2019s National Health Insurance Research Database. J Diabetes Complications. 2014;28(5):612\u20136.","journal-title":"J Diabetes Complications"},{"key":"350_CR26","doi-asserted-by":"crossref","first-page":"f2267","DOI":"10.1136\/bmj.f2267","volume":"346","author":"D Eurich","year":"2013","unstructured":"Eurich D, Simpson S, Senthilselvan A, Asche C, Sandhu-Minhas J, McAlister F. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ. 2013;346:f2267.","journal-title":"BMJ"},{"key":"350_CR27","doi-asserted-by":"crossref","unstructured":"Chen D-Y, Wang S-H, Mao C-T, Tsai M-L, Lin Y-S, Su F-C, Chou C-C, Wen M-S, Wang C-C, Hsieh I-C. Sitagliptin After ischemic stroke in type 2 diabetic patients: a nationwide cohort study. Medicine 2015;94(28).","DOI":"10.1097\/MD.0000000000001128"},{"issue":"6","key":"350_CR28","doi-asserted-by":"crossref","first-page":"e0131122","DOI":"10.1371\/journal.pone.0131122","volume":"10","author":"S-H Wang","year":"2015","unstructured":"Wang S-H, Chen D-Y, Lin Y-S, Mao C-T, Tsai M-L, Hsieh M-J, Chou C-C, Wen M-S, Wang C-C, Hsieh I-C. Cardiovascular outcomes of sitagliptin in type 2 diabetic patients with acute myocardial infarction, a population-based cohort study in Taiwan. PLoS ONE. 2015;10(6):e0131122.","journal-title":"PLoS ONE"},{"issue":"2","key":"350_CR29","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1464-5491.2004.01416.x","volume":"22","author":"M Muis","year":"2005","unstructured":"Muis M, Bots M, Grobbee D, Stolk R. Insulin treatment and cardiovascular disease; friend or foe? A point of view. Diabetic Med. 2005;22(2):118\u201326.","journal-title":"Diabetic Med"},{"issue":"2","key":"350_CR30","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jdiacomp.2014.11.012","volume":"29","author":"Y Huang","year":"2015","unstructured":"Huang Y, Abdelmoneim AS, Light P, Qiu W, Simpson SH. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. J Diabetes Complicat. 2015;29(2):196\u2013202.","journal-title":"J Diabetes Complicat"},{"key":"350_CR31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12933-014-0123-x","volume":"13","author":"S-H Chang","year":"2014","unstructured":"Chang S-H, Wu L-S, Chiou M-J, Liu J-R, Yu K-H, Kuo C-F, Wen M-S, Chen W-J, Yeh Y-H, See L-C. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol. 2014;13:123.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"350_CR32","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1463-1326.2009.01040.x","volume":"11","author":"E Bosi","year":"2009","unstructured":"Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009;11(5):506\u201315.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"350_CR33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000353679","volume":"36","author":"C-J Lu","year":"2013","unstructured":"Lu C-J, Sun Y, Muo C-H, Chen R-C, Chen P-C, Hsu CY. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study. Cerebrovasc Diseases. 2013;36(2):145\u201351.","journal-title":"Cerebrovasc Diseases"},{"issue":"8","key":"350_CR34","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/pds.2165","volume":"20","author":"KB Filion","year":"2011","unstructured":"Filion KB, Joseph L, Boivin JF, Suissa S, Brophy JM. Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus. Pharmacoepidemiol Drug Saf. 2011;20(8):785\u201396.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"350_CR35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2210-11-5","volume":"11","author":"S Berthet","year":"2011","unstructured":"Berthet S, Olivier P, Montastruc J-L, Lapeyre-Mestre M. Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database. BMC Pharmacol Toxicol. 2011;11(1):5.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"12","key":"350_CR36","doi-asserted-by":"crossref","first-page":"e28157","DOI":"10.1371\/journal.pone.0028157","volume":"6","author":"AM Gallagher","year":"2011","unstructured":"Gallagher AM, Smeeth L, Seabroke S, Leufkens H, Van Staa TP. Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data. PLoS ONE. 2011;6(12):e28157.","journal-title":"PLoS ONE"},{"issue":"23","key":"350_CR37","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1161\/01.CIR.0000103683.99399.7E","volume":"108","author":"RW Nesto","year":"2003","unstructured":"Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S. Thiazolidinedione use, fluid retention, and congestive heart failure a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108(23):2941\u20138.","journal-title":"Circulation"},{"key":"350_CR38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1475-2840-13-81","volume":"13","author":"E Standl","year":"2014","unstructured":"Standl E, Theodorakis MJ, Erbach M, Schnell O, Tuomilehto J. On the potential of acarbose to reduce cardiovascular disease. Cardiovasc Diabetol. 2014;13:81.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"350_CR39","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1464-5491.2004.01149.x","volume":"21","author":"R Heine","year":"2004","unstructured":"Heine R, Balkau B, Ceriello A, Del Prato S, Horton E, Taskinen MR. What does postprandial hyperglycaemia mean? Diabet Med. 2004;21(3):208\u201313.","journal-title":"Diabet Med"},{"issue":"4","key":"350_CR40","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1463-1326.2009.01160.x","volume":"12","author":"L Nalysnyk","year":"2010","unstructured":"Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 2010;12(4):288\u201398.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"350_CR41","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1210\/jc.2005-1566","volume":"91","author":"M Shimabukuro","year":"2006","unstructured":"Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab. 2006;91(3):837\u201342.","journal-title":"J Clin Endocrinol Metab"},{"key":"350_CR42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1475-2840-9-12","volume":"9","author":"T Kato","year":"2010","unstructured":"Kato T, Inoue T, Node K. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol. 2010;9:12.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"350_CR43","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jcjd.2015.02.002","volume":"39","author":"OHY Yu","year":"2015","unstructured":"Yu OHY, Yin H, Azoulay L. The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death. Can J Diabetes. 2015;39(5):383\u20139.","journal-title":"Can J Diabetes"},{"issue":"5","key":"350_CR44","doi-asserted-by":"crossref","first-page":"e0124287","DOI":"10.1371\/journal.pone.0124287","volume":"10","author":"J-M Seong","year":"2015","unstructured":"Seong J-M, Choi N-K, Shin J-Y, Chang Y, Kim Y-J, Lee J, Kim J-Y, Park B-J. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study. PLoS ONE. 2015;10(5):e0124287.","journal-title":"PLoS ONE"},{"key":"350_CR45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4236\/jdm.2014.41006","volume":"4","author":"H Onuma","year":"2014","unstructured":"Onuma H, Inukai K, Watanabe M, Sumitani Y, Hosaka T, Ishida H. Effects of long-term monotherapy with glimepiride vs glibenclamide on glycemic control and macrovascular events in Japanese Type 2 diabetic patients. J Diabetes Mellitus. 2014;4:33\u20137.","journal-title":"J Diabetes Mellitus"},{"key":"350_CR46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1475-2840-13-15","volume":"13","author":"I Nakamura","year":"2014","unstructured":"Nakamura I, Oyama J-I, Komoda H, Shiraki A, Sakamoto Y, Taguchi I, Hiwatashi A, Komatsu A, Takeuchi M, Yamagishi S-I. Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report. Cardiovasc Diabetol. 2014;13:15.","journal-title":"Cardiovasc Diabetol"},{"key":"350_CR47","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1053\/euhj.1998.1242","volume":"20","author":"H Klepzig","year":"1999","unstructured":"Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker K, Kiowski W, Amann F, Gruber D, Harris S. Sulfonylureas and ischaemic preconditioning. Eur Heart J. 1999;20:439\u201346.","journal-title":"Eur Heart J"},{"issue":"5","key":"350_CR48","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/dmrr.621","volume":"22","author":"T Sato","year":"2006","unstructured":"Sato T, Nishida H, Miyazaki M, Nakaya H. Effects of sulfonylureas on mitochondrial ATP-sensitive K\u00a0+\u00a0channels in cardiac myocytes: implications for sulfonylurea controversy. Diabetes Metab Res Rev. 2006;22(5):341\u20137.","journal-title":"Diabetes Metab Res Rev"},{"issue":"6","key":"350_CR49","doi-asserted-by":"crossref","first-page":"500","DOI":"10.2188\/jea.JE20140076","volume":"24","author":"C-L Cheng","year":"2014","unstructured":"Cheng C-L, Lee C-H, Chen P-S, Li Y-H, Lin S-J, Yang Y-HK. Validation of acute myocardial infarction cases in the national health insurance research database in Taiwan. J Epidemiol. 2014;24(6):500.","journal-title":"J Epidemiol"},{"issue":"3","key":"350_CR50","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jfma.2013.09.009","volume":"114","author":"C-Y Hsieh","year":"2015","unstructured":"Hsieh C-Y, Chen C-H, Li C-Y, Lai M-L. Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. J Formos Med Assoc. 2015;114(3):254\u20139.","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"350_CR51","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12933-015-0294-0","volume":"14","author":"EZ Fisman","year":"2015","unstructured":"Fisman EZ, Tenenbaum A. Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovasc Diabetol. 2015;14(1):129.","journal-title":"Cardiovasc Diabetol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-016-0350-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:22:02Z","timestamp":1567642922000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cardiab.com\/content\/15\/1\/41"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["350"],"URL":"https:\/\/doi.org\/10.1186\/s12933-016-0350-4","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,1]]},"article-number":"41"}}